Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by equities research analysts at Leerink Partners from $980.00 to $862.00 in a research note issued on Tuesday.

Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of AbbVie in a research note issued to investors on Monday, February 3rd. Leerink ...

Crown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced the successful closing of its acquisition of Revance Therapeutics, ...

The business combination reinforces Crown's position as a leading, innovative, high-growth aesthetics and skincare company JOHNSON CITY, Tenn., Feb. 6, 2025 /PRNewswire/ ...

BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company with a market capitalization of $14.57 ...

Fintel reports that on February 6, 2025, Leerink Partners downgraded their outlook for Hologic (NasdaqGS:HOLX) from Outperform to Market Perform. Analyst Price Forecast Suggests 20.21% Upside As of ...

The firm's legal troubles continue to mount, with their latest courtroom challenge tied to a $50 million loan to one of its ...

Good afternoon and welcome to the Hologic's first quarter fiscal 2025 earnings conference call. My name is Lisa and I'm your operator for today's call. Today's conference is being recorded. All lines ...

Welcome to McKesson's third-quarter fiscal 2025 earnings conference call. Please be advised that today's conference is being recorded. At this time, I'd like to turn the call over to Rachel Rodriguez, ...

NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of ...